IQVIA Technologies develops purpose-built solutions on a future-state architecture to enable connected intelligence across the entire life sciences product lifecycle. Under our Orchestrated Clinical Trials (OCT) platform, we’re driving smarter, faster trials for sponsors, sites and patients, with more than 20 market-leading, cloud-based products and tech-enabled services such as GrantPlan, Investigator Site Portal, Clinical Trial Payments, eTMF, IRT, and eConsent. These best-of-breed technologies are available independently of our CRO services, with support models customized to meet your specific business  needs.


  • In this webinar we will be exploring how to manage a supply chain through IRT with self service tools and actionable insights as well as best practices for supply forecasting and overstock management.

  • After a decade of dabbling with eConsent, how can sponsors and technology providers meet the demand to bring clinical trials directly to the patient at a global scale? In this webinar, you’ll learn strategies to overcome the persistent challenges in eConsent adoption and gain the benefits promised from successful decentralized trials with remote capabilities for patients and sites.

  • Alnylam Pharmaceuticals is developing an entirely new class of medicines and delivered the world’s first and only approved RNAi therapeutics in 2018 and 2019. Learn how Alnylam earned its reputation among investigators as a sponsor of choice by standardizing studies on a collaborative portal more than 6 years ago and leveraging technology to deliver results.

  • This 20-minute webinar gives the latest information from hands-on experience with eConsent implementations for new and ongoing trials in the COVID-19 era. Learn about the benefits that can be gained from remote consent for patients and sites and the changing regulatory landscape that is enabling adoption in a growing number of countries and regions.

  • Deploying a successful global program for paying clinical research sites is an achievable and worthwhile goal but requires an understanding of the differences in frameworks and motivations. Learn what is needed to pays site globally in a reliable, timely, and equitable manner.

  • The global pandemic has brought the need to enrol new patients quickly in COVID19-related trials and keep patient engagement high in ongoing trials, even as face-to-face interactions are limited. This presentation will review sponsor and site frequently asked questions about electronic and remote consent capabilities as they seek to consent patients in new and faster ways.

  • This short video explains how and why business process outsourcing (BPO) using IQVIA Technologies for site payments offers excellent ROI for sponsors and peace of mind for sites and investigators.


IQVIA Technologies

4820 Emperor Blvd

Durham, NC 27703


Phone: 1-888-336-3748

Contact: Turquiose Ross, MBA


  • When it comes to gaining the benefits of electronic consent (eConsent) in clinical trials, site adoption is the key. Explore the steps up the ladder of eConsent adoption and reach new heights with every study.

  • Cenduit IRT study design teams took-on the challenges pressing biopharmaceutical industry sponsors as they worked to digitally enable sites and speed time to first-patient-in for COVID-19 therapeutic and vaccine trials.

  • More than 80 percent of sites surveyed want to get paid in 30 days, and many clinical technology companies offer specialized software solutions to help manage several components of the site payments process. However, these systems still require a large effort by the sponsor to operate. What is the secret sauce for success?

  • Year after year, slow and unpredictable investigator payments continue to be a top complaint from clinical study sites. Explore Bayer's Automated Site Payment Invoice Resolution project in the available white paper.

  • eClinical technologies are becoming more commonplace in drug development as biopharma adopts validated methods to maintain compliance; patient recruitment, engagement and safety; and supply chain forecasting. This white paper illustrates how sponsors are using electronic solutions for Drug Accountability (DA), because they recognize the significant increase in efficiency and accuracy that these methods provide.

  • Electronic consent (eConsent) technology has existed for nearly 20 years in various iterations. Read how sponsors overall have taken a cautious approach to using eConsent, piloting it on individual studies but refraining from incorporating it across all pipelines in clinical operations.

  • Electronic trial master file (eTMF) systems are proving to be effective in planning, managing, monitoring, and maintaining inspection-readiness and compliance. This paper explores the use of planning wizards and how placeholder creation promotes study completeness, timely document uploading, and reduced rates of quality control failures. These features can ease workloads while providing the transparency needed for inspections and audits.

  • When Alnylam Pharmaceuticals began development of medicines for rare diseases with few or no treatment options, the company’s leaders knew they needed to design clinical trials that kept patient well-being and disease burden at the forefront. As Alnylam’s first clinical program began in 2014, the study team saw emerging site-facing technologies as a foundation for those trusted relationships, starting with a purpose-built communication channel and easy-to-use study conduct tools to support a complex protocol.

  • Two of America’s greatest assets are its diverse demographics and its relentless pursuit of new medicines and treatments to improve patient lives worldwide. Unfortunately, it’s a widely known (but little discussed) challenge that the two do not go hand in hand. Minority participation in clinical trials is staggeringly deficient.

  • After go-live, the sponsor learned its study did not fit the existing IRT solution, affecting data quality, timelines, and drug supply shipments. The legacy system’s medication management algorithm could not support the required flexibility in the supply chain. The trial included an adaptive cohort design. Read how Cenduit delivered a high-quality study achieved through innovation, close client collaboration, and expert project management.

  • Trial design for a medicine trial to investigate treatment for non-small cell lung cancer presents unique challenges. These include the need for an IRT platform that can support the rapid incorporation of amendments and account for multiple or potential arms which require different lists of material types and dosages that could be prescribed to patients and supplied to sites. Cenduit’s highly-configurable, flexible technology platform was the solution.

  • A Top 5 global pharmaceutical company wanted to help sites do everyday tasks more efficiently, making it easier for site staff to adhere to the protocol and deliver high-quality data. After evaluations and pilots, the company deployed IQVIA Technologies’ Investigator Site Portal (formerly DrugDev) in a 4-phase approach that delivered benefits each step of the way.

  • Conducting feasibility is an essential and necessary step to starting up a clinical trial. The good news is that the whole approach has the ability to change for the better by initiating and adopting some enhancements.

  • Building an accurate budget for a clinical trial comes with a host of challenges. These include, but are not limited to, intricate protocols, large enrollments, shortened timelines and global sites. By using a benchmarking tool that uses a global dataset experts can develop Fair market Value (FMV) costs.

  • With so much new and updated information being shared on nearly a daily basis, it’s important to consider the most effective methods of organization and distribution. Here are some best practices we’ve compiled from working with sponsors and sites of all sizes and specialties during the COVID-19 pandemic.  

  • Many people have questions on the topic of remote consent in a hospital setting, particularly when the patient is quite ill and requires a legally acceptable representative (LAR) to consent on his or her behalf. This article shares insights gained through real-world implementations.

  • Digital solutions previously viewed as “nice to have” for clinical trial optimization are now proving to be vital to support sites. Here are five areas where we have seen sponsors take advantage of digital clinical technologies to boost support to sites and enable innovative drug development to continue - not only during the COVID-19 crisis but well into the future.

  • For the clinical research industry, COVID-19 poses immediate and longer-term challenges. Sharing experiences is vital to our industry, now more than ever. Here I share the most frequently asked questions about eConsent technology, along with our responses, since it may be of value to your organization at this time.

  • The COVID-19 pandemic is presenting unprecedented challenges to the clinical trial industry. Sites are in an unprecedented state of flux, and the pressure to understand the situation, protect patients and providers, and determine how to ensure continuity is on. Now more than ever, strong communication channels between sponsors and sites are critical.

  • Site satisfaction is closely linked to the frequency, accuracy and timeliness of clinical trial payments. Yet making payments has long been a challenging process between sponsors and sites. This white paper reviews five common issues that delay site payments and offers recommendations to resolve these issues, improving payment efficiencies and ultimately site satisfaction.